Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 273

Similar articles for PubMed (Select 19481572)

1.

Emerging role of glutamate in the pathophysiology of major depressive disorder.

Hashimoto K.

Brain Res Rev. 2009 Oct;61(2):105-23. doi: 10.1016/j.brainresrev.2009.05.005. Epub 2009 May 28. Review.

PMID:
19481572
2.

The role of glutamate on the action of antidepressants.

Hashimoto K.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1558-68. doi: 10.1016/j.pnpbp.2010.06.013. Epub 2010 Jun 20. Review.

PMID:
20600468
3.

Ketamine and other potential glutamate antidepressants.

Dutta A, McKie S, Deakin JF.

Psychiatry Res. 2015 Jan 30;225(1-2):1-13. doi: 10.1016/j.psychres.2014.10.028. Epub 2014 Nov 13. Review.

PMID:
25467702
5.
6.

Glutamate and depression: clinical and preclinical studies.

Paul IA, Skolnick P.

Ann N Y Acad Sci. 2003 Nov;1003:250-72. Review.

PMID:
14684451
7.

Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Mathews DC, Henter ID, Zarate CA.

Drugs. 2012 Jul 9;72(10):1313-33. doi: 10.2165/11633130-000000000-00000. Review.

8.

Targeting of NMDA receptors in the treatment of major depression.

Dang YH, Ma XC, Zhang JC, Ren Q, Wu J, Gao CG, Hashimoto K.

Curr Pharm Des. 2014;20(32):5151-9.

PMID:
24410564
9.

Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.

Niciu MJ, Ionescu DF, Richards EM, Zarate CA Jr.

J Neural Transm. 2014 Aug;121(8):907-24. doi: 10.1007/s00702-013-1130-x. Epub 2013 Dec 8. Review.

PMID:
24318540
10.

Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.

Owen RT.

Drugs Today (Barc). 2012 Jul;48(7):469-78. doi: 10.1358/dot.2012.48.7.1832873. Review.

PMID:
22844658
11.

Glutamate in the enteric nervous system.

Kirchgessner AL.

Curr Opin Pharmacol. 2001 Dec;1(6):591-6. Review.

PMID:
11757814
12.
13.

On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants.

Pałucha A, Pilc A.

Pol J Pharmacol. 2002 Nov-Dec;54(6):581-6. Review.

14.

Metabotropic glutamate receptors in the control of mood disorders.

Witkin JM, Marek GJ, Johnson BG, Schoepp DD.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):87-100. Review.

PMID:
17430147
15.

Glutamate-based antidepressants: 20 years on.

Skolnick P, Popik P, Trullas R.

Trends Pharmacol Sci. 2009 Nov;30(11):563-9. doi: 10.1016/j.tips.2009.09.002. Review.

PMID:
19837463
16.

AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression.

Chourbaji S, Vogt MA, Fumagalli F, Sohr R, Frasca A, Brandwein C, Hörtnagl H, Riva MA, Sprengel R, Gass P.

FASEB J. 2008 Sep;22(9):3129-34. doi: 10.1096/fj.08-106450. Epub 2008 May 20.

17.

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R.

Psychopharmacology (Berl). 2003 Sep;169(3-4):215-33. Epub 2003 Sep 2. Review.

PMID:
12955285
18.

Intravenous ketamine for treatment-resistant major depressive disorder.

Covvey JR, Crawford AN, Lowe DK.

Ann Pharmacother. 2012 Jan;46(1):117-23. doi: 10.1345/aph.1Q371. Epub 2011 Dec 20. Review.

PMID:
22190250
19.

Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: implications for schizophrenia.

Zavitsanou K, Nguyen V, Newell K, Ballantyne P, Huang XF.

J Chem Neuroanat. 2008 Oct;36(2):71-6. doi: 10.1016/j.jchemneu.2008.06.004. Epub 2008 Jul 2.

PMID:
18640263
20.

The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: therapeutic potential.

Doraiswamy PM.

Curr Neurol Neurosci Rep. 2003 Sep;3(5):373-8. Review.

PMID:
12914679
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk